Reaching a higher Mounjaro dose: what the progression actually looks like

You've been on Mounjaro for a few weeks and wondering whether your dose is 'working yet'

It's a question our prescribers hear often, and if you're sitting at 2.5 mg feeling impatient, that's entirely understandable. The first pen's job is to help your body adjust to tirzepatide, slowing gastric emptying and engaging both GIP and GLP-1 receptors for the first time. Appetite suppression at this stage can feel modest, and that's expected. The NHS guidance on tirzepatide explains that the starting dose is a tolerability measure, not the level at which most people see significant weight change.

From 2.5 mg, progression moves in 4-weekly steps: 5 mg, then 7.5 mg, then 10 mg, 12.5 mg, and finally 15 mg. Whether you stay at an intermediate dose or move upward depends on how your body is responding and how well each dose is tolerated. Some people find a dose in the middle of the range suits them well; others progress to the top, and if you're wondering what the highest dose of Mounjaro actually is and what reaching it involves, that page explains it clearly. For a detailed look at how each specific step fits into the overall picture, the Mounjaro dose guide covers the full schedule in plain terms.

One thing worth knowing: a prescriber can keep you at a given dose for longer than four weeks if tolerability needs more time. There's no clinical pressure to reach 15 mg. The therapeutic goal is meaningful, sustained weight loss alongside manageable side effects, not hitting a number on the pen.

What the evidence shows at the higher doses of tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity (no diabetes) across three doses of tirzepatide (5 mg, 10 mg and 15 mg) and placebo over 72 weeks. Average weight reductions at the 10 mg dose were around 19.5%, and at 15 mg around 20–21%. These are trial-population averages; individual results vary, and the trial was conducted alongside a reduced-calorie diet and increased activity.

The higher the dose, the stronger the average result in the data, but also the more important tolerability becomes. Gastrointestinal effects such as nausea, looser stools and reduced appetite tend to be most noticeable in the first days after a dose increase, and usually settle within a week or two for most people. If they don't, that's a conversation to have with your prescriber rather than a reason to push on regardless.

For people weighing up whether tirzepatide's ceiling is meaningfully different from semaglutide's, the SURMOUNT-5 head-to-head trial (2025) showed greater average weight reduction with tirzepatide than with semaglutide 2.4 mg. NICE's appraisal of tirzepatide (TA1026) references this comparative evidence in its recommendations. If you want to understand what the clinical picture looks like specifically at the upper end of the schedule, the page on high dose tirzepatide goes into that in more detail.

If you're curious whether 7.5 mg is already considered a high dose in clinical terms, the page on whether 7.5 mg counts as a high dose addresses that directly.

What higher doses mean for eligibility and monitoring

Moving to a higher dose of Mounjaro through a private pharmacy like nume isn't automatic. Every repeat order receives a clinical review before it's approved. For patients requesting a dose increase, that review includes a check of evidence, weight recorded at the current dose, any side-effect history, and whether progression is clinically appropriate. This isn't bureaucracy for its own sake; it's the standard the GPhC expects of responsible online prescribing.

Transfer patients arriving already on a higher dose are asked to provide evidence of their current treatment before that dose is continued. The prescriber makes a fresh assessment each time. If you're thinking about what moving to a Mounjaro higher dose involves in practice, including what the prescriber will want to see before approving that step, that page sets out the detail clearly.

NICE recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related condition on the NHS, lower BMI thresholds apply for some ethnic backgrounds. Private eligibility follows the licensed criteria: adults with a BMI of 30 or above, or 27 or above alongside a qualifying condition such as hypertension, high cholesterol, obstructive sleep apnoea or type 2 diabetes. BMI alone doesn't determine suitability; the prescriber looks at the full picture. More on that at the weight-loss treatment overview.

Cost is a practical question at higher doses, since pricing reflects the strength of the pen. If you want to understand how Mounjaro is priced across the dose range in the private market, the guide to getting Mounjaro through an online pharmacy covers the context honestly, including what a legitimate price includes and what to watch out for.

When to talk to your prescriber, and when to get medical help

Most people tolerate dose increases well, particularly when they're spaced by the recommended four weeks. But some symptoms warrant a call sooner rather than later. Severe or persistent stomach pain that spreads toward the back (with or without vomiting) can be a sign of pancreatitis and needs urgent medical attention. The MHRA highlighted this in a Drug Safety Update for GLP-1 medicines earlier this year. Signs of dehydration from prolonged vomiting or diarrhoea, gallbladder symptoms, or an allergic reaction are also reasons to seek help promptly rather than wait for the next routine check-in.

For questions that are less urgent (whether to slow down your titration, whether a side effect is typical at this dose, or how long to stay at your current level) your prescriber is the right person to ask. At nume, aftercare support runs seven days a week precisely because questions don't always arise on a Monday morning. If you'd like to explore whether progression to a higher dose is right for your situation, the free consultation is the place to start that conversation with a GPhC-registered prescriber.